Thyrocare Q2 Profit Falls About 68% to Rs 15.2 Crore
The diagnostics company booked an impairment of about Rs 45 crore on its Nueclear Healthcare stake as revenue grew about 25%.
Key Takeaways
- Consolidated net profit fell about 68% year on year to about Rs 15.2 crore in Q2 FY27.
- Thyrocare booked an impairment loss of about Rs 45 crore on Nueclear Healthcare.
- Revenue from operations rose about 25% to about Rs 270.8 crore.
- Thyrocare is selling its entire stake in Nueclear Healthcare for about Rs 141.4 crore.
- The sale needs shareholder approval.
Thyrocare's consolidated net profit for the September 2026 quarter (Q2 FY27) fell about 68% year on year to about Rs 15.2 crore, as the diagnostics company booked an impairment loss of about Rs 45 crore on its radiology subsidiary. Revenue from operations rose about 25% to about Rs 270.8 crore over the same period.
The impairment relates to Nueclear Healthcare Limited (NHL). Thyrocare is selling its entire stake in NHL for about Rs 141.4 crore.
Thyrocare Q2 FY27 at a glance
| Detail | Value |
|---|---|
| Quarter | Q2 FY27, quarter ended September 30, 2026 |
| Basis | Consolidated |
| Net profit | About Rs 15.2 crore, against about Rs 47.8 crore a year earlier |
| Change in profit | Down about 68% year on year |
| Revenue from operations | About Rs 270.8 crore, against about Rs 216.5 crore a year earlier |
| Change in revenue | Up about 25% year on year |
| Impairment loss on Nueclear Healthcare | About Rs 45 crore |
How an impairment of about Rs 45 crore pulled Thyrocare's profit down
Thyrocare Technologies runs diagnostic testing and also has an imaging services business through Nueclear Healthcare. In Q2 FY27, the company took an impairment loss of about Rs 45 crore on its investment in NHL, an exceptional charge that sits inside the consolidated profit figure.
The company is divesting its entire shareholding in NHL for about Rs 141.4 crore, paid as a mix of cash and compulsorily convertible preference shares.
| Period | Consolidated figures |
|---|---|
| Q2 FY26 (quarter ended September 2025) | Revenue about Rs 216.5 crore, net profit about Rs 47.8 crore |
| Q1 FY27 (quarter ended June 2026) | Revenue about Rs 240 crore, net profit about Rs 51.3 crore |
| Q2 FY27 (quarter ended September 2026) | Revenue about Rs 270.8 crore, net profit about Rs 15.2 crore |
Thyrocare on the Nueclear Healthcare sale
Thyrocare said it is seeking shareholder approval for the sale.
Where Thyrocare's numbers stand after Q2 FY27
Thyrocare's consolidated profit of about Rs 15.2 crore in Q2 FY27 compares with about Rs 51.3 crore in the previous quarter and about Rs 47.8 crore a year earlier. Revenue from operations of about Rs 270.8 crore was about 13% higher than the about Rs 240 crore reported in Q1 FY27.
More news
Frequently Asked Questions
What is Thyrocare's Q2 FY27 consolidated net profit?
How much did Thyrocare's profit fall year on year in Q2 FY27?
Why did Thyrocare's profit fall in Q2 FY27?
What is Nueclear Healthcare?
How much is Thyrocare selling Nueclear Healthcare for?
How much revenue did Thyrocare earn in Q2 FY27?
How much did Thyrocare's revenue grow in Q2 FY27?
What was Thyrocare's revenue in the previous quarter?
What was Thyrocare's revenue in Q2 FY26?
What was Thyrocare's profit in the previous quarter?
Are Thyrocare's Q2 FY27 figures consolidated or standalone?
What did Thyrocare say about the Nueclear Healthcare sale?
More in Business
Ambuja Cements Q2 Profit Falls About 90% to Rs 236 Crore
Ambuja Cements' Q2 consolidated profit fell about 90% as the year-earlier base had a tax reversal.
Trent Q2 Consolidated Profit Rises 25% to Rs 468 Crore
Trent's consolidated profit rose 25% to Rs 468 crore in Q2 FY27 as revenue grew 22%.
Fino Payments Bank Posts Rs 20.9 Crore Loss in Q2 FY27
Fino Payments Bank reported a Rs 20.9 crore loss for the September quarter as total income fell.